Latest News

Russia restricts abortion drug sales until 2030

The Russian government is tightening restrictions on access to abortion-inducing drugs.

Russia’s Ministry of Health announced Tuesday new limits on abortion drug distribution and sales at pharmacies. 

Misoprostol and mifepristone are specifically being targeted with the restrictions. The two drugs are now limited by subject-quantitative registration, according to translations from the Moscow Times. 

The restrictions will go into effect on Sep. 1, 2024 and last for exactly six years.

Health Minister Mikhail Murashko first suggested adding the two abortion drugs to the registry in July, saying they pose both medical and ethical risks for Russian women. 

Russia is currently experiencing a cultural shift in its attitudes toward abortion. Previously rather liberal on the issue, the country’s leadership and conservative communities have seized the current climate to propagate anti-abortion regulations. 

The Russian Orthodox Church — which enjoys a historically significant relationship with the nation’s politics — is also vehemently opposed to abortion on the basis of Christian morals.

Under the new restrictions, individuals seeking the drug will need to obtain a prescription from a doctor before purchasing. 

Additionally, medical providers will require a special license to provide the abortion-inducing medication to patients. 

Providers will also have to track and report their distribution of the drugs.

This post appeared first on FOX NEWS

You May Also Like

Latest News

Ahead of a planned trip to China this week, U.S. Secretary of State Antony Blinken is reported to have alleged that Beijing is still...

Stock

The rise of Asian fast fashion retailer Shein already has Amazon on alert, but its plans of selling proprietary supply-chain technology and services to...

Latest News

A Biden appointee, who has donated tens of thousands of dollars to his campaigns and is married to a top former aide of then-Sen....

Latest News

Minnesota Gov. Tim Walz is facing scrutiny from Republicans over what they say are pro-China remarks, including an interview in which the Democratic vice...

Disclaimer: Greycardinalbussiness.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 Greycardinalbussiness.com

Exit mobile version